Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Response to August 21, 2009 Letter - Menveo

Our STN: BL 125300/0

Novartis Vaccines and Diagnostics, Inc.
Attention: Chris Webster, Ph D
350 Massachusetts Ave
Cambridge, MA, 02139

Dear Dr. Webster:

We have received your August 21, 2009, resubmission to your biologics license application for Meningococcal Polysaccharide (Serogroups A, C, Y, W-135) CRM197 Conjugate Vaccine, for the active immunization of individuals 11-55 years of age, for the prevention of disease caused by N. meningitis serogroups A/C/Y/W-135 on August 21, 2009.

We consider this a complete, Class 2 response to our action letter. Therefore, the user fee goal date is February 20, 2010.

If you have any questions, please contact the primary reviewer, Cara Fiore, PhD, at (301) 827-3070.

Sincerely yours

Wellington Sun, M.D.

/signature/

Director
Division of Vaccines and Related Product Applications
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 09/24/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English